Kazia Therapeutics Limited
KZIANASDAQHealthcare● Active
$11.40
+$0.41(+3.73%)
Market Cap$18465617
P/E Ratio—
52W High$17.4
52W Low$4.86
Kazia Therapeutics Limited (KZIA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KZIA · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.04M | $2.31M | $0.00M | $0.01M | $15.18M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.04M | $2.31M | $0.00M | $0.01M | $15.18M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $7.33M | $17.38M | $15.56M | $20.17M | $14.54M |
| G&A Expenses | $8.72M | $13.56M | $8.58M | $5.11M | $7.02M |
| Total Operating Expenses | $14.26M | $30.77M | $24.12M | $25.41M | $21.56M |
| Operating Income | ($14.22M) | ($28.46M) | ($24.12M) | ($25.40M) | ($6.38M) |
| Operating Margin %(computed) | — | — | — | — | -41.99% |
| Interest Income | $0.07M | $0.01M | $0.02M | $0.00M | $0.04M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($22.45M) | ($27.05M) | ($20.74M) | ($25.38M) | ($8.90M) |
| Income Tax Expense | ($1.75M) | ($0.27M) | ($0.27M) | ($0.37M) | ($0.48M) |
| Net Income | ($20.70M) | ($26.78M) | ($20.47M) | ($25.01M) | ($8.42M) |
| Net Margin %(computed) | — | — | — | — | -55.46% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-18.90 | $-55.00 | $-55.00 | $-95.00 | $-35.80 |
| Wtd Avg Shares | 1.10M | 0.48M | 0.37M | 0.27M | 0.24M |
| EBITDA | ($13.28M) | ($26.59M) | ($22.28M) | ($23.52M) | ($5.11M) |
| EBITDA Margin %(computed) | — | — | — | — | -33.66% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · AUD · M
Explore more Kazia Therapeutics Limited data
About Kazia Therapeutics Limited (KZIA) Income Statement
Kazia Therapeutics Limited (KZIA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, KZIA reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.02B) — a net profit margin of -49290.48%.
Frequently asked questions
KZIA · 4 questionsKazia Therapeutics Limited (KZIA) reported revenue of $0.00B for 2025, down 98.2% year-over-year.
KZIA revenueKZIA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09